BioNTech
NEWS
While COVID-19 appears to be surging again in the U.S. and Europe, the government is spending billions to acquire antibody and antiviral therapies and edging toward vaccination boosters.
Between the numerous COVID-19 vaccines and several new antiviral drugs, it would appear that the tools to end the COVID-19 pandemic are within reach. Here’s a look at some of the top stories.
The total revenue for the quarter was $9.74 billion, a leap of 47%. The COVID-19 vaccine, Vaxzevria, only contributed 1% to the company’s profit.
Between January 4, 2020 and October 30, 2021, COVID-19 accounted for 576 deaths among children 17 and younger, compared to 189 from influenza, according to the CDC.
Pfizer and BioNTech requested the FDA authorize booster shots for their COVID-19 vaccine for all adults 18 years and older, presenting data not available in September.
New studies come out regularly supporting the efficacy and safety of the COVID-19 vaccines. Here’s a look as well as other COVID-19 news.
Researchers aren’t sure why the mRNA vaccines appear to cause myocarditis symptoms. The FDA said the risk appears more after the second dose. Find more here.
Vaccinations will be required by January 4 under the new White House plan.
The decision follows a 14-0 vote among members of an expert panel advising the agency.
JOBS
IN THE PRESS